Revumenib Pill Shows Promise Against Leukemia in Early Trial
In a study out this week, scientists describe a novel experimental pill that may be able to help patients with a difficult-to-treat form of leukemia. Nearly half of patients in the Phase I trial responded to the treatment, called revumenib, while about a third experienced a complete remission of their cancer. More research will be needed to confirm its effectiveness, however.Revumenib is being developed by the company Syndax. It’s meant to work by inhibiting a protein called menin, which seems to play an important role in…